EAU 2021

REVIEW UroToday

Viewing 1-20 of 127 articles

EAU 2021: Discussant: Phase 3 KEYNOTE-564 Study

EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis

EAU 2021: Time on Treatment with Abiraterone and Enzalutamide in the Patient-Overview Prostate Cancer in the National Prostate Cancer Register of Sweden

EAU 2021: Treatment Options for De-Novo mHSPC: Future: Personalized Medicine for mHSPC?

EAU 2021: Impact of Prior Local Therapy on Survival in mCRPC: Results from COU-AA-302 Trial

EAU 2021: Treatment Options for De-Novo mHSPC: Local Treatment: Surgery (Primary +/- Lymph Nodes)

EAU 2021: Treatment Options for De-Novo mHSPC: Systemic Treatments: How to Choose the Right Treatment for the Right Patient

EAU 2021: Treatment Options for De-Novo mHSPC: Local Treatment: Radiation Therapy (Primary +/- Lymph Nodes)

EAU 2021: Identification of the Best Candidates for PSMA PET/CT Among Patients Experiencing Biochemical Recurrence After Radical Prostatectomy: A New Tool to Optimize of Patient Selection

EAU 2021: Gaps in the Evidence: Adjuvant Versus Early Salvage Radiotherapy

EAU 2021: Gaps in the Evidence: Optimal Treatment for cN1 Patients

EAU 2021: Intraprostatic Recurrences on PSMA PET/CT After Prostate Whole Gland Radiotherapy: Is Histological Confirmation Necessary?

EAU 2021: Long-Term Validation on the Impact of PSMA-PET on Metastasis-Free Survival in a Large Salvage Radiotherapy Cohort

EAU 2021: Should We Perform PSMA PET/CT in the Initial Staging of Prostate Cancer? A Pro Versus Con Debate

EAU 2021: Preoperative PSMA PET/CT as a Predictor of Biochemical Persistence and Early Biochemical Recurrence

EAU 2021: Association of Local Progression with Deterioration of Urinary Symptoms and Occurrence of Genitourinary Adverse Events (AEs) in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post Hoc Analysis of PROSPER

EAU 2021: Evolving Landscape of First-Line Systemic Treatment in Metastatic Renal Cell Carcinoma

EAU 2021: Predicting Early Biochemical Progression in Prostate Cancer Patients Staged with PSMA PET and Multiparametric Magnetic Resonance Imaging

EAU 2021: Standardized Uptake Values as Determined on PSMA PET/CT Are Associated with Higher Gleason Grade and Lower Biochemical-Free Recurrence Rates in Patients with Prostate Cancer

EAU 2021: Preliminary Results from the PEDAL Trial: A Prospective Single Arm Paired Comparison of Ability to Diagnose and Locate Prostate Cancer Between Multiparametric MRI and 18F-PSMA-PET/CT

1
2
3
4
5
6
7